Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors)

Authors

  • Jeffrey D. Seidman M.D.,

    Corresponding author
    1. Department of Pathology, Washington Hospital Center, Washington, DC
    • Department of Pathology, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010
    Search for more papers by this author
    • Fax: (202) 877-5263

  • Robert J. Kurman M.D.

    1. Departments of Gynecology, Obstetrics and Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Search for more papers by this author

  • See accompanying editorial on pages 677–80 and referenced original article on pages 791–800, this issue.

Abstract

Ovarian serous borderline tumors recently were categorized into benign and malignant types. A subset of these tumors, termed “micropapillary serous carcinoma (MPSC),” is reported to behave in a manner similar to low-grade carcinoma. In this issue of Cancer, Bristow et al. report their experience with 26 patients with recurrent MPSC.

See also pages 677–80 and pages 791–800.

Ancillary